{"classes":[{"categories":[{"measurements":[{"comment":"Not estimable based on the Kaplan-Meier method because of insufficient follow up time","groupId":"OG000","lowerLimit":"356","upperLimit":"NA","value":"NA"},{"comment":"Not estimable based on the Kaplan-Meier method because of insufficient follow up time","groupId":"OG001","lowerLimit":"555","upperLimit":"NA","value":"631"},{"comment":"Not estimable based on the Kaplan-Meier method because of insufficient follow up time","groupId":"OG002","lowerLimit":"778","upperLimit":"NA","value":"NA"},{"comment":"Not estimable based on the Kaplan-Meier method because of insufficient follow up time","groupId":"OG003","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"48"},{"groupId":"OG002","value":"33"},{"groupId":"OG003","value":"17"}],"units":"Participants"}],"description":"Progression-free survival is defined as time from the date of randomization to the date of the first documented progressive disease or death.\n\nDisease progression requires any one or more of the following: serum m-protein increase \\>= 25% from nadir(absolute increase \\>= 0.5 g/dL); Urine m-protein increase \\>= 25% from nadir(absolute increase \\>= 200 mg/24 hr), bone marrow plasma cell percentage increase \\>= 25% from nadir(absolute increase \\>= 10%), new bone lesion or soft tissue plasmacytomas.","dispersionType":"95% Confidence Interval","groups":[{"description":"Bortezomib: 1.3 mg/m\\^2/dose IV on Days 1, 4, 8, and 11 of a 3-week cycle for 8 cycles, then on Days 1, 8, 15, and 22 of a 6-week cycle for 4 cycles.\n\nDexamethasone: 40 mg orally \\[PO\\] on Days 1, 8, and 15 of a 3-week cycle for 8 cycles, then stop.\n\nLenalidomide: 25 mg PO on Days 1 through 14 of a 3-week cycle for 8 cycles, then stop.","id":"OG000","title":"V-DR"},{"description":"Bortezomib: 1.3 mg/m\\^2/dose IV on Days 1, 4, 8, and 11 of a 3-week cycle for 8 cycles, then on Days 1, 8, 15, and 22 of a 6-week cycle for 4 cycles.\n\nDexamethasone: 40 mg PO on Days 1, 8, and 15 of a 3-week cycle for 8 cycles, then stop.\n\nCyclophosphamide: 500 mg/m\\^2 dose PO on Days 1 and 8 of a 3-week cycle for 8 cycles, then stop.\n\nLenalidomide: 15 mg PO on Days 1 through 14 of a 3-week cycle for 8 cycles, then stop.","id":"OG001","title":"VDCR"},{"description":"Bortezomib: 1.3 mg/m\\^2/dose IV on Days 1, 4, 8, and 11 of a 3-week cycle for 8 cycles, then on Days 1, 8, 15, and 22 of a 6-week cycle for 4 cycles.\n\nDexamethasone: 40 mg orally PO on Days 1, 8, and 15 of a 3-week cycle for 8 cycles, then stop.\n\nCyclophosphamide: 500 mg/m\\^2 dose PO on Days 1 and 8 of a 3-week cycle for 8 cycles, then stop.","id":"OG002","title":"V-DC"},{"description":"Bortezomib: 1.3 mg/m\\^2/dose IV on Days 1, 4, 8, and 11 of a 3-week cycle for 8 cycles, then on Days 1, 8, 15, and 22 of a 6-week cycle for 4 cycles.\n\nDexamethasone: 40 mg PO on Days 1, 8, and 15 of a 3-week cycle for 8 cycles, then stop.\n\nCyclophosphamide: 500 mg/m\\^2 dose PO on Days 1, 8, and 15 of a 3-week cycle for 8 cycles, then stop.","id":"OG003","title":"VDC-mod"}],"paramType":"MEDIAN","populationDescription":"The modified intent-to-treat population is defined as phase 2 patients received at least one dose of any drug.","reportingStatus":"POSTED","timeFrame":"Up to 48 weeks or until disease progression/death","title":"Progression-free Survival","type":"SECONDARY","unitOfMeasure":"days"}